Articles

Capivasertib plus fulvestrant’s PFS advantage benefitted a broader patient population, and overall survival (OS) data with improved biomarker analyses can now be reported. Read More ›

Updated data from the EMBER trial of imlunestrant, a new oral selective estrogen receptor degrader showing sustained inhibition of estrogen receptor (ER)-dependent gene transcription and cell proliferation, have been released. Read More ›

Sacituzumab govitecan (SG) showed a significant survival benefit over single-agent chemotherapy treatment of physician’s choice (TPC) in the pivotal phase 3 ASCENT trial. Read More ›

The 3-year extended follow-up of CheckMate 9LA demonstrated that first-line nivolumab plus ipilimumab in combination with limited chemotherapy resulted in long-term, durable clinical benefit compared with chemotherapy alone in patients with metastatic NSCLC, regardless of PD-L1 mutation status. Read More ›

The PIONeeR trial identified 37 biomarkers that could predict resistance to anti–PD-1/PD-L1 therapy before treatment initiation. Read More ›

The safety profile of durvalumab ± tremelimumab plus chemotherapy was manageable, but with more immune-related adverse events observed with durvalumab and tremelimumab. Read More ›

Camrelizumab plus albumin paclitaxel and apatinib resulted in promising antitumor activity with an acceptable safety profile for first-line treatment of advanced NSCLC. Read More ›

MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor, showed promising antitumor activity and durable clinical benefit and was tolerated at doses 1500 mg. Read More ›

Analysis of the changes in blood circulating soluble proteins resulted in identifying potential response biomarkers to immune checkpoint inhibitors in patients with squamous-cell lung cancer. Read More ›

Safe and effective therapeutic options are needed in patients with advanced myelofibrosis and high-risk mutations. Bomedemstat demonstrated improvements in symptoms and spleen responses in patients previously treated with ruxolitinib. Read More ›